Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Summary

Primary Objective: * To assess the long term safety of Sarilumab (SAR153191/REGN88) in participants with ankylosing spondylitis (AS) Secondary Objective: * To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in participants with AS

Timeline

Start

2010-06

Primary completion

2011-12

Completion

2011-12

Drugs

Indications